カテゴリ： MarketsandMarkets, 世界, 医療/バイオ

抗体薬物複合体（ADC）の世界市場予測（～2028）：製品別、リンカー種類別、ペイロード種類別、ターゲット別、疾患別、地域別

■ 英語タイトル：Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028

調査会社MarketsandMarkets社が発行したリサーチレポート（データ管理コード：BT8808-23）■ 発行会社/調査会社：MarketsandMarkets
■ 商品コード：BT8808-23
■ 発行日：2023年10月17日
■ 調査対象地域：グローバル
■ 産業分野：バイオテクノロジー
■ ページ数：273
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧）USD4,950 ⇒換算￥752,400見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥1,010,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥1,238,800見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[抗体薬物複合体（ADC）の世界市場予測（～2028）：製品別、リンカー種類別、ペイロード種類別、ターゲット別、疾患別、地域別]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

"抗体薬物複合体（ADC）の世界市場規模は2023年の97億米ドルから2028年には198億米ドルに達すると予測され、予測期間中の年平均成長率は15.2%" 癌の有病率の上昇、臨床研究中の堅牢な製品、産業連携の増加などの要因が市場成長を促進すると考えられます。例えば、2023年8月、イミュノジェン社は、武田薬品工業株式会社と、日本におけるエラヒールの開発および商業化に関する独占的提携を締結しました。

"抗体薬物複合体（ADC）市場ではKadcylaセグメントが圧倒的シェアを獲得"
製品に基づき、世界の抗体薬物複合体（ADC）市場はKadcyla、Enhertu、Adcetris、Padcev、Trodelvy、Polivy、その他に区分されます。2022年にはKadcylaセグメントが市場の最大シェアを占めました。 乳がん治療にKadcylaが広く使用されていることが、市場の成長を促進すると考えられます。
市場の成長を牽引すると思われます。PolivyとAdcertisの様々な適応症に対する最近の承認は、今後数年間で市場をさらに押し上げる可能性があります。

"2022年の疾患タイプ別では乳がん分野が最大シェア"
疾患タイプに基づき、抗体薬物複合体（ADC）市場は乳がん、肺がん、その他の疾患に区分されます。2022年には、乳がんセグメントが抗体薬物複合体（ADC）市場で最大のシェアを占めました。同セグメントは、乳がんの有病率の増加や乳がんに対するADCの需要の高まりなど、さまざまな要因によって市場で圧倒的なシェアを占めています。バイオシミラー医薬品の上市は、市場成長にさらに好影響を与えそうです。

"アジア太平洋地域はより速いペースで成長しそう"
抗体薬物複合体（ADC）市場は、北米、欧州、アジア太平洋、中南米、中東・アフリカに区分されます。アジア太平洋地域は予測期間中に大きなCAGRで成長すると予測されています。中国と日本におけるADCの政府承認の増加、インドでの乳がん治療用バイオシミラーUjviraの発売は、同地域の市場成長に弾みをつけると思われます。

本レポートのために実施した一次インタビューは以下のように分類されます。
- 回答者別 供給側80％、需要側20%
- 回答者の役職別（サプライサイド） 管理職 - 45%、CXOおよび取締役 - 30%、経営幹部 - 25%
- 地域別 北米 -40%、欧州 -25%、アジア太平洋地域 -20%、中南米 -10%、中東・アフリカ -5%

レポート掲載企業一覧
• F. Hoffmann-La Roche Ltd (Switzerland)
• Daiichi Sankyo Company, Limited (Japan)
• Seagen Inc. (US)
• Gilead Sciences, Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• Pfizer Inc. (US),
• Astellas Pharma Inc (Japan)
• AstraZeneca (UK)
• ADC Therapeutics SA (Switzerland)
• ImmunoGen, Inc. (US)
• Zydus Group (India)
• Abbvie Inc. (US)
• Ambrx (US)
• LegoChem Biosciences, Inc. (South Korea)
• Byondis (Netherlands)
• ProfoundBio (China)
• RemeGen (China)
• Sutro Biopharma, Inc. (US)
• Lepu Biopharma CO., Ltd. (China)
• Zymeworks Inc. (Canada)
• Mersana Therapeutics (US)
• Duality Biologics (China)
• LaNova Medicines (China)
• Exelixis, Inc. (US)
• BiOneCure Therapeutics Inc. (US)
• Tripartite Therapeutics, Inc. (Taiwan).

調査範囲
この調査レポートは、抗体薬物複合体（ADC）市場の詳細な状況を掲載しています。製品、投与経路、疾患タイプ、用途、タイプ、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの会社概要、最近の動向、主要市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、抗体薬物複合体（ADC）市場全体とそのサブセグメントについて、最も近似した収益数字を提供することで、市場リーダーや新規参入者を支援します。また、利害関係者が競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートにより、関係者は市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を得ることができます。

本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因（がんの罹患率の上昇、新規ADC開発のための主要市場プレイヤーによる投資と提携の増加、臨床試験中のADC数の増加、ADC開発に対する規制当局の支援）、阻害要因（高い製造コスト、ADCに関連する副作用、製品開発における高い消耗率）、機会（併用療法の採用、新興経済圏での高い成長、先進的ADCの出現）、および課題（技術的な複雑さ）が抗体薬物複合体（ADC）市場の成長に影響を与えていることを分析しています。
- 製品開発/イノベーション：抗体薬物複合体（ADC）市場の新製品に関する詳細な洞察を提供します。
- 市場開発：有利な市場に関する包括的情報 - 当レポートでは、さまざまな地域の抗体医薬複合体市場を分析しています。
- 市場の多様化：抗体薬物複合体（ADC）市場における新サービス、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。
- 競合他社の評価：F. Hoffmann-La Roche Ltd (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India)などの主要企業を分析しています。

1 イントロダクション
2 調査方法
3 エグゼクティブサマリー
4 プレミアムインサイト
5 市場概要
6 抗体薬物複合体（ADC）の世界市場：製品別
7 抗体薬物複合体（ADC）の世界市場：リンカータイプ別
8 抗体薬物複合体（ADC）の世界市場：標的タイプ別
9 抗体薬物複合体（ADC）の世界市場：ペイロードタイプ別
10 抗体薬物複合体（ADC）の世界市場：疾患タイプ別
11 抗体薬物複合体（ADC）の世界市場：地域別
12 競争状況
13 企業情報
14 付録

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

1 INTRODUCTION 37
1.1 STUDY OBJECTIVES 37
1.2 MARKET DEFINITION 37
1.2.1 INCLUSIONS AND EXCLUSIONS 38
1.3 MARKET SCOPE 38
1.3.1 MARKETS COVERED 38
1.3.2 YEARS CONSIDERED 39
1.3.3 CURRENCY CONSIDERED 39
1.4 RESEARCH LIMITATIONS 39
1.5 STAKEHOLDERS 40
1.6 RECESSION IMPACT 40
2 RESEARCH METHODOLOGY 41
2.1 RESEARCH DATA 41
FIGURE 1 RESEARCH DESIGN 41
2.1.1 SECONDARY DATA 41
2.1.2 PRIMARY DATA 42
FIGURE 2 ANTIBODY DRUG CONJUGATES MARKET: BREAKDOWN OF PRIMARIES 43
2.2 MARKET SIZE ESTIMATION 44
FIGURE 3 ANTIBODY DRUG CONJUGATES MARKET: MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS (2022) 44
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS) 44
FIGURE 5 ANTIBODY DRUG CONJUGATES MARKET: REVENUE SHARE ANALYSIS OF F-HOFFMAN LA ROCHE LTD. 45
2.2.1 PRIMARY INSIGHTS 46
FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 46
2.2.2 SEGMENT ASSESSMENT METHODOLOGY 46
FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 46
2.3 GROWTH RATE ASSUMPTIONS 47
FIGURE 8 ANTIBODY DRUG CONJUGATES MARKET: CAGR PROJECTION ANALYSIS 48
FIGURE 9 ANTIBODY DRUG CONJUGATES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 48
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 49
FIGURE 10 DATA TRIANGULATION METHODOLOGY 49
2.5 STUDY ASSUMPTIONS 50
2.6 RISK ANALYSIS 50
2.7 RECESSION IMPACT ANALYSIS 50
TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2024–2028 (% GROWTH) 51
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 51
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 51
3 EXECUTIVE SUMMARY 52
FIGURE 11 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2023 VS. 2028 (USD MILLION) 52
FIGURE 12 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2023 VS. 2028 (USD MILLION) 53
FIGURE 13 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2023 VS. 2028 (USD MILLION) 53
FIGURE 14 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2023 VS. 2028 (USD MILLION) 54
FIGURE 15 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2023 VS. 2028 (USD MILLION) 55
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF ANTIBODY DRUG CONJUGATES MARKET 56
4 PREMIUM INSIGHTS 57
4.1 ANTIBODY DRUG CONJUGATES MARKET OVERVIEW 57
FIGURE 17 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD 57
4.2 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE AND COUNTRY (2022) 58
FIGURE 18 BREAST CANCER SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN ANTIBODY DRUG CONJUGATES MARKET IN 2022 58
4.3 ANTIBODY DRUG CONJUGATES MARKET SHARE, BY PRODUCT, 2023 VS. 2028 58
FIGURE 19 KADCYLA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 58
4.4 ANTIBODY DRUG CONJUGATES: GEOGRAPHIC GROWTH OPPORTUNITIES 59
FIGURE 20 ASIA PACIFIC COUNTRIES TO REGISTER HIGHER GROWTH RATES FROM 2023 TO 2028 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
FIGURE 21 ANTIBODY DRUG CONJUGATES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
TABLE 4 ANTIBODY DRUG CONJUGATES MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
5.2.1 DRIVERS 61
5.2.1.1 Rising incidence of cancer 61
TABLE 5 GLOBAL INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2035 62
5.2.1.2 Increasing investments for ADC development 63
5.2.1.3 Growing number of ADCs in clinical trials 64
TABLE 6 ASSET RANKING FOR LEADING ADC DEVELOPERS (2019 VS. 2023) 64
5.2.1.4 Favorable regulatory support 66
5.2.2 RESTRAINTS 66
5.2.2.1 High manufacturing costs 66
5.2.2.2 Side effects associated with ADCs 67
5.2.2.3 High attrition rate in product development 67
TABLE 7 LIST OF DISCONTINUED ANTIBODY DRUG CONJUGATES (2020−2022) 67
5.2.3 OPPORTUNITIES 68
5.2.3.1 Adoption of combination therapies 68
5.2.3.2 High growth in emerging economies 69
5.2.3.3 Emergence of advanced ADCs 69
5.2.4 CHALLENGES 70
5.2.4.1 Technical complexities 70
5.3 PIPELINE ANALYSIS 70
FIGURE 22 ANTIBODY DRUG CONJUGATES MARKET: CLINICAL TRIALS 70
5.4 VALUE CHAIN ANALYSIS 71
FIGURE 23 ANTIBODY DRUG CONJUGATES MARKET: VALUE CHAIN ANALYSIS 71
5.5 ECOSYSTEM ANALYSIS 74
5.5.1 ROLE IN ECOSYSTEM 74
5.6 TECHNOLOGY ANALYSIS 75
TABLE 8 LEADING TECHNOLOGICAL ADVANCEMENTS FOR ADC GENERATIONS 75
5.7 REGULATORY ASSESSMENT 77
5.7.1 FDA REGULATIONS ON ANTIBODY DRUG CONJUGATES 77
5.7.1.1 CLINICAL PHARMACOLOGY CONSIDERATIONS 77
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 9 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 78
TABLE 10 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
TABLE 11 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 12 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
TABLE 13 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
5.8 PORTER’S FIVE FORCES ANALYSIS 81
TABLE 14 ANTIBODY DRUG CONJUGATES MARKET: PORTER’S FIVE FORCES ANALYSIS 81
5.8.1 INTENSITY OF COMPETITIVE RIVALRY 81
5.8.2 BARGAINING POWER OF SUPPLIERS 82
5.8.3 BARGAINING POWER OF BUYERS 82
5.8.4 THREAT OF SUBSTITUTES 82
5.8.5 THREAT OF NEW ENTRANTS 82
5.9 PATENT ANALYSIS 83
5.9.1 LIST OF MAJOR PATENTS 84
5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85
FIGURE 24 GROWING USE OF ACDS FOR ONCOLOGY AND OTHER CHRONIC DISEASES TO DRIVE MARKET 85
5.11 PRICING ANALYSIS 85
TABLE 15 ANTIBODY DRUG CONJUGATES MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY REGION 85
TABLE 16 ANTIBODY DRUG CONJUGATES MARKET: PRICING ANALYSIS OF ADC PRODUCTS, BY KEY PLAYERS 86
5.12 KEY CONFERENCES AND EVENTS 86
TABLE 17 ANTIBODY DRUG CONJUGATES MARKET: DETAILED LIST OF EVENTS AND CONFERENCES (2023−2024) 86
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 87
FIGURE 25 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND INFLUENCE ON BUYING PROCESS 87
FIGURE 26 KEY BUYING CRITERIA FOR ADC PRODUCTS AMONG END USERS 87
6 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT 89
6.1 INTRODUCTION 90
TABLE 18 ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 90
6.2 KADCYLA 90
6.2.1 LAUNCH OF BIOSIMILARS TO DRIVE MARKET 90
TABLE 19 ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY REGION, 2021–2028 (USD MILLION) 91
TABLE 20 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 21 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 22 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION) 92
TABLE 23 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR KADCYLA, BY COUNTRY, 2021–2028 (USD MILLION) 93
6.3 ENHERTU 93
6.3.1 RISING INCIDENCE OF BREAST CANCER TO PROPEL MARKET 93
TABLE 24 ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY REGION, 2021–2028 (USD MILLION) 94
TABLE 25 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 26 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 27 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 28 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ENHERTU, BY COUNTRY, 2021–2028 (USD MILLION) 95
6.4 ADCETRIS 96
6.4.1 GROWING CASES OF HODGKIN LYMPHOMA TO DRIVE MARKET 96
TABLE 29 ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 30 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 31 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 32 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 33 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR ADCETRIS, BY COUNTRY, 2021–2028 (USD MILLION) 98
6.5 PADCEV 99
6.5.1 RISING INCIDENCE OF UROTHELIAL CANCER TO DRIVE MARKET 99
TABLE 34 ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV MARKET, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 35 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 36 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 37 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 38 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR PADCEV, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.6 TRODELVY 101
6.6.1 INCREASING GOVERNMENT APPROVALS FOR BREAST CANCER TO DRIVE MARKET 101
TABLE 39 ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 40 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION) 102
TABLE 41 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 42 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 43 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR TRODELVY, BY COUNTRY, 2021–2028 (USD MILLION) 103
6.7 POLIVY 104
6.7.1 RISING PREVALENCE OF NON-HODGKIN LYMPHOMA TO PROPEL MARKET 104
TABLE 44 ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 45 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 46 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 47 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 48 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR POLIVY, BY COUNTRY, 2021–2028 (USD MILLION) 106
6.8 OTHER PRODUCTS 106
TABLE 49 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 50 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 51 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 52 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 53 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2021–2028 (USD MILLION) 108
7 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE 109
7.1 INTRODUCTION 110
TABLE 54 ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 110
7.2 CLEAVABLE LINKERS 110
7.2.1 HIGH COMPATIBILITY WITH BROAD RANGE OF DRUGS TO DRIVE MARKET 110
TABLE 55 ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 56 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 57 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 58 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 59 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 112
7.3 NON-CLEAVABLE LINKERS 113
7.3.1 LOW TOXICITY LEVELS TO SUPPORT MARKET GROWTH 113
TABLE 60 ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY REGION, 2021–2028 (USD MILLION) 113
TABLE 61 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 62 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 63 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 64 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR NON-CLEAVABLE LINKERS, BY COUNTRY, 2021–2028 (USD MILLION) 115
8 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE 116
8.1 INTRODUCTION 117
TABLE 65 ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 117
8.2 HER2 117
8.2.1 RISING PREVALENCE OF BREAST CANCER TO DRIVE MARKET 117
TABLE 66 ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 67 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 68 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 69 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 70 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR HER2, BY COUNTRY, 2021–2028 (USD MILLION) 119
8.3 CD22 120
8.3.1 INCREASING CASES OF B-CELL LYMPHOMAS TO DRIVE MARKET 120
TABLE 71 ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 72 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION) 120
TABLE 73 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 74 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 75 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD22, BY COUNTRY, 2021–2028 (USD MILLION) 121
8.4 CD30 122
8.4.1 INCREASING CLINICAL TRIALS FOR PRODUCT LAUNCHES TO SUPPORT MARKET GROWTH 122
TABLE 76 ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY REGION, 2021–2028 (USD MILLION) 122
TABLE 77 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 78 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 79 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION) 123
TABLE 80 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CD30, BY COUNTRY, 2021–2028 (USD MILLION) 124
8.5 OTHER TARGET TYPES 124
TABLE 81 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY REGION, 2021–2028 (USD MILLION) 124
TABLE 82 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 83 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 84 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 85 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER TARGET TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 126
9 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE 127
9.1 INTRODUCTION 128
TABLE 86 ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 128
9.2 MONOMETHYL AURISTATIN E 128
9.2.1 CYTOTOXIC PAYLOAD FOR ADC DEVELOPMENT TO DRIVE MARKET 128
TABLE 87 ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 88 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 89 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 90 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 91 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MONOMETHYL AURISTATIN E, BY COUNTRY, 2021–2028 (USD MILLION) 130
9.3 CALICHEAMICIN 131
9.3.1 LAUNCH OF CALICHEAMICIN-BASED ADCS TO PROPEL MARKET 131
TABLE 92 ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 93 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 94 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 95 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 96 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR CALICHEAMICIN, BY COUNTRY, 2021–2028 (USD MILLION) 132
9.4 MAYTANSINOIDS 133
9.4.1 INNOVATIVE PRODUCT PIPELINE TO SUPPORT MARKET GROWTH 133
TABLE 97 ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY REGION, 2021–2028 (USD MILLION) 133
TABLE 98 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 99 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 100 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION) 134
TABLE 101 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR MAYTANSINOIDS, BY COUNTRY, 2021–2028 (USD MILLION) 135
9.5 OTHER PAYLOAD TYPES 135
TABLE 102 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 103 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 104 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 105 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 106 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER PAYLOAD TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 137
10 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE 138
10.1 INTRODUCTION 139
TABLE 107 ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 139
10.2 BREAST CANCER 139
10.2.1 RISING CASES OF INFLAMMATORY BREAST CANCER TO DRIVE MARKET 139
TABLE 108 PROJECTION OF BREAST CANCER RATES 140
TABLE 109 ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 110 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 111 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 112 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 113 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BREAST CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 142
10.3 BLOOD CANCER 143
10.3.1 INCREASING FOCUS ON CLINICAL TRIALS FOR ADVANCED CONJUGATES TO PROPEL MARKET 143
TABLE 114 GLOBAL INCIDENCE OF BLOOD CANCER 143
TABLE 115 ESTIMATED NEW BLOOD CANCER CASES IN US (2023) 143
TABLE 116 ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 117 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 118 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 119 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 120 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR BLOOD CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 145
10.4 OTHER DISEASE TYPES 146
TABLE 121 ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY REGION, 2021–2028 (USD MILLION) 146
TABLE 122 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 123 EUROPE: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 124 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 125 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET FOR OTHER DISEASE TYPES, BY COUNTRY, 2021–2028 (USD MILLION) 147
11 ANTIBODY DRUG CONJUGATES MARKET, BY REGION 148
11.1 INTRODUCTION 149
TABLE 126 ANTIBODY DRUG CONJUGATES MARKET, BY REGION, 2021–2028 (USD MILLION) 149
11.2 NORTH AMERICA 149
FIGURE 27 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT 150
TABLE 127 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 128 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 151
TABLE 129 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 151
TABLE 130 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 152
TABLE 131 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 152
TABLE 132 NORTH AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 152
11.2.1 US 153
11.2.1.1 Rising regulatory approvals for ADCs to drive market 153
TABLE 133 US: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 153
TABLE 134 US: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 154
TABLE 135 US: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 154
TABLE 136 US: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 154
TABLE 137 US: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 155
11.2.2 CANADA 155
11.2.2.1 High R&D investments for novel ADCs to propel market 155
TABLE 138 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 156
TABLE 139 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 156
TABLE 140 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 157
TABLE 141 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 157
TABLE 142 CANADA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 157
11.2.3 NORTH AMERICA: RECESSION IMPACT 158
11.3 EUROPE 158
TABLE 143 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 144 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 159
TABLE 145 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 159
TABLE 146 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 159
TABLE 147 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 160
TABLE 148 EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 160
11.3.1 GERMANY 160
11.3.1.1 Increasing collaborations among market players for cancer therapeutics to propel market 160
TABLE 149 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 161
TABLE 150 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 161
TABLE 151 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 162
TABLE 152 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 162
TABLE 153 GERMANY: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 162
11.3.2 FRANCE 163
11.3.2.1 Growing demand for personalized therapeutics to drive market 163
TABLE 154 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 163
TABLE 155 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 164
TABLE 156 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 164
TABLE 157 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 164
TABLE 158 FRANCE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 165
11.3.3 UK 165
11.3.3.1 Increasing cancer burden to support market growth 165
TABLE 159 UK: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 166
TABLE 160 UK: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 166
TABLE 161 UK: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 166
TABLE 162 UK: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 167
TABLE 163 UK: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 167
11.3.4 ITALY 167
11.3.4.1 Rising industrial collaborations for ADC production to drive market 167
TABLE 164 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 168
TABLE 165 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 168
TABLE 166 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 169
TABLE 167 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 169
TABLE 168 ITALY: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 169
11.3.5 SPAIN 170
11.3.5.1 Rising focus on drug discovery to support market growth 170
TABLE 169 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 170
TABLE 170 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 171
TABLE 171 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 171
TABLE 172 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET, 2021–2028 (USD MILLION) 171
TABLE 173 SPAIN: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 172
11.3.6 REST OF EUROPE 172
TABLE 174 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 173
TABLE 175 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 173
TABLE 176 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 174
TABLE 177 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 174
TABLE 178 REST OF EUROPE: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 174
11.3.7 EUROPE: RECESSION IMPACT 175
11.4 ASIA PACIFIC 175
FIGURE 28 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET SNAPSHOT 176
TABLE 179 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 177
TABLE 180 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 177
TABLE 181 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 178
TABLE 182 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 178
TABLE 183 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 178
TABLE 184 ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 179
11.4.1 CHINA 179
11.4.1.1 Rising initiatives for advanced therapies to drive market 179
TABLE 185 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 180
TABLE 186 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 180
TABLE 187 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 181
TABLE 188 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 181
TABLE 189 CHINA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 181
11.4.2 JAPAN 182
11.4.2.1 Favorable regulatory support to propel market 182
TABLE 190 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 183
TABLE 191 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 183
TABLE 192 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 184
TABLE 193 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 184
TABLE 194 JAPAN: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 184
11.4.3 INDIA 185
11.4.3.1 Emergence of innovative biosimilars to drive market 185
TABLE 195 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 185
TABLE 196 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 186
TABLE 197 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 186
TABLE 198 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 186
TABLE 199 INDIA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 187
11.4.4 REST OF ASIA PACIFIC 187
TABLE 200 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 188
TABLE 201 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 188
TABLE 202 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 189
TABLE 203 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 189
TABLE 204 REST OF ASIA PACIFIC: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 189
11.4.5 ASIA PACIFIC: RECESSION IMPACT 190
11.5 LATIN AMERICA 190
TABLE 205 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 206 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 191
TABLE 207 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 191
TABLE 208 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 192
TABLE 209 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 192
TABLE 210 LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 192
11.5.1 BRAZIL 193
11.5.1.1 Regulatory approvals for breast cancer therapeutics to drive market 193
TABLE 211 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 193
TABLE 212 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 194
TABLE 213 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 194
TABLE 214 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET, 2021–2028 (USD MILLION) 194
TABLE 215 BRAZIL: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 195
11.5.2 REST OF LATIN AMERICA 195
TABLE 216 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 196
TABLE 217 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 196
TABLE 218 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 197
TABLE 219 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 197
TABLE 220 REST OF LATIN AMERICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 197
11.5.3 LATIN AMERICA: RECESSION IMPACT 198
11.6 MIDDLE EAST & AFRICA 198
11.6.1 RISING PRODUCT LAUNCHES FOR CANCER THERAPEUTICS TO SUPPORT MARKET GROWTH 198
TABLE 221 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PRODUCT, 2021–2028 (USD MILLION) 199
TABLE 222 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY LINKER TYPE, 2021–2028 (USD MILLION) 199
TABLE 223 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY PAYLOAD TYPE, 2021–2028 (USD MILLION) 200
TABLE 224 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY TARGET TYPE, 2021–2028 (USD MILLION) 200
TABLE 225 MIDDLE EAST & AFRICA: ANTIBODY DRUG CONJUGATES MARKET, BY DISEASE TYPE, 2021–2028 (USD MILLION) 200
11.7 MIDDLE EAST & AFRICA: RECESSION IMPACT 201

12 COMPETITIVE LANDSCAPE 202
12.1 INTRODUCTION 202
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 202
TABLE 226 ANTIBODY DRUG CONJUGATES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 202
12.3 REVENUE SHARE ANALYSIS 203
FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2019–2022) 204
12.4 MARKET SHARE ANALYSIS 204
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 204
TABLE 227 ANTIBODY DRUG CONJUGATES MARKET: INTENSITY OF COMPETITIVE RIVALRY 205
12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS 206
FIGURE 31 ANTIBODY DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX (2022) 207
12.5.1 STARS 207
12.5.2 EMERGING LEADERS 207
12.5.3 PERVASIVE PLAYERS 208
12.5.4 PARTICIPANTS 208
12.6 COMPETITIVE BENCHMARKING OF 25 PLAYERS 208
12.6.1 PRODUCT FOOTPRINT OF 11 COMPANIES 208
TABLE 228 ANTIBODY DRUG CONJUGATES MARKET: COMPANY FOOTPRINT ANALYSIS OF KEY PLAYERS 208
TABLE 229 ANTIBODY DRUG CONJUGATES MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 209
12.6.2 REGIONAL FOOTPRINT OF 26 COMPANIES 210
TABLE 230 ANTIBODY DRUG CONJUGATES MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 210
12.7 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 211
FIGURE 32 ANTIBODY DRUG CONJUGATES MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 211
12.7.1 PROGRESSIVE COMPANIES 211
12.7.2 STARTING BLOCKS 212
12.7.3 RESPONSIVE COMPANIES 212
12.7.4 DYNAMIC COMPANIES 212
12.8 COMPETITIVE BENCHMARKING OF STARTUPS/SMES 212
TABLE 231 ANTIBODY DRUG CONJUGATES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 212
TABLE 232 ANTIBODY DRUG CONJUGATES MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES 215
12.9 COMPETITIVE SCENARIO AND TRENDS 216
12.9.1 PRODUCT LAUNCHES 216
TABLE 233 ANTIBODY DRUG CONJUGATES MARKET: PRODUCT LAUNCHES (JANUARY 2020–JUNE 2023) 216
12.9.2 DEALS 217
TABLE 234 ANTIBODY DRUG CONJUGATES MARKET: DEALS (JANUARY 2020−JUNE 2023) 217
13 COMPANY PROFILES 219
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
13.1 KEY PLAYERS 219
13.1.1 F. HOFFMANN-LA ROCHE LTD. 219
TABLE 235 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 219
FIGURE 33 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 220
13.1.2 DAIICHI SANKYO COMPANY, LIMITED 222
TABLE 236 DAIICHI SANKYO COMPANY, LIMITED: BUSINESS OVERVIEW 222
FIGURE 34 DAIICHI SANKYO COMPANY, LIMITED: COMPANY SNAPSHOT (2022) 223
13.1.3 SEAGEN INC. 228
TABLE 237 SEAGEN INC.: BUSINESS OVERVIEW 228
FIGURE 35 SEAGEN INC.: COMPANY SNAPSHOT (2022) 228
13.1.4 GILEAD SCIENCES, INC. 233
TABLE 238 GILEAD SCIENCES, INC.: BUSINESS OVERVIEW 233
FIGURE 36 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2022) 234
13.1.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED 236
TABLE 239 TAKEDA PHARMACEUTICAL COMPANY LIMITED: BUSINESS OVERVIEW 236
FIGURE 37 TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2022) 237
13.1.6 PFIZER INC. 239
TABLE 240 PFIZER INC.: BUSINESS OVERVIEW 239
FIGURE 38 PFIZER INC.: COMPANY SNAPSHOT (2022) 240
13.1.7 ASTELLAS PHARMA INC. 241
TABLE 241 ASTELLAS PHARMA INC.: BUSINESS OVERVIEW 241
FIGURE 39 ASTELLAS PHARMA INC: COMPANY SNAPSHOT (2022) 242
13.1.8 ASTRAZENECA 244
TABLE 242 ASTRAZENECA: BUSINESS OVERVIEW 244
FIGURE 40 ASTRAZENECA: COMPANY SNAPSHOT (2022) 245
13.1.9 ADC THERAPEUTICS SA 248
TABLE 243 ADC THERAPEUTICS SA: BUSINESS OVERVIEW 248
FIGURE 41 ADC THERAPEUTICS SA: COMPANY SNAPSHOT (2022) 248
13.1.10 IMMUNOGEN, INC. 251
TABLE 244 IMMUNOGEN, INC.: BUSINESS OVERVIEW 251
FIGURE 42 IMMUNOGEN, INC.: COMPANY SNAPSHOT (2022) 251
13.1.11 ZYDUS GROUP 254
TABLE 245 ZYDUS GROUP: BUSINESS OVERVIEW 254
FIGURE 43 ZYDUS GROUP: COMPANY SNAPSHOT (2022) 254
13.2 OTHER PLAYERS 256
13.2.1 ABBVIE INC. 256
TABLE 246 ABBVIE INC.: BUSINESS OVERVIEW 256
13.2.2 AMBRX 258
TABLE 247 AMBRX: BUSINESS OVERVIEW 258
13.2.3 LEGOCHEM BIOSCIENCES, INC. 259
TABLE 248 LEGOCHEM BIOSCIENCES, INC.: BUSINESS OVERVIEW 259
13.2.4 BYONDIS 261
TABLE 249 BYONDIS: BUSINESS OVERVIEW 261
13.2.5 PROFOUNDBIO 262
TABLE 250 PROFOUNDBIO: BUSINESS OVERVIEW 262
13.2.6 REMEGEN 263
TABLE 251 REMEGEN: BUSINESS OVERVIEW 263
13.2.7 SUTRO BIOPHARMA, INC. 265
TABLE 252 SUTRO BIOPHARMA, INC.: BUSINESS OVERVIEW 265
13.2.8 LEPU BIOPHARMA CO., LTD. 267
TABLE 253 LEPU BIOPHARMA CO., LTD.: BUSINESS OVERVIEW 267
13.2.9 ZYMEWORKS INC. 268
TABLE 254 ZYMEWORKS INC.: BUSINESS OVERVIEW 268
13.2.10 MERSANA THERAPEUTICS 269
TABLE 255 MERSANA THERAPEUTICS: BUSINESS OVERVIEW 269
13.2.11 DUALITY BIOLOGICS 270
TABLE 256 DUALITY BIOLOGICS: BUSINESS OVERVIEW 270
13.2.12 LANOVA MEDICINES 271
TABLE 257 LANOVA MEDICINES: BUSINESS OVERVIEW 271
13.2.13 EXELIXIS, INC. 272
TABLE 258 EXELIXIS, INC.: BUSINESS OVERVIEW 272
13.2.14 BIONECURE THERAPEUTICS INC. 273
TABLE 259 BIONECURE THERAPEUTICS INC.: BUSINESS OVERVIEW 273
13.2.15 TRIPARTITE THERAPEUTICS, INC. 274
TABLE 260 TRIPARTITE THERAPEUTICS, INC.: BUSINESS OVERVIEW 274
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
14 APPENDIX 275
14.1 DISCUSSION GUIDE 275
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 280
14.3 CUSTOMIZATION OPTIONS 282
14.4 RELATED REPORTS 282
14.5 AUTHOR DETAILS 283

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 微小管阻害薬の世界市場2022-2028：重合阻害剤、解重合阻害剤、微小管ダイナミクス阻害剤、抗体薬物複合体（ADC）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(BT8808-23 )"抗体薬物複合体（ADC）の世界市場予測（～2028）：製品別、リンカー種類別、ペイロード種類別、ターゲット別、疾患別、地域別" (英文：Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。